Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Stopped early · Phase 2

Conditions studied: Spasms, Infantile

In brief

Infantile Spasms (IS) is a diagnosis described as a fairly rare and terrible form of epilepsy that usually strikes children in the first year of life. There is a great need for safe and effective therapies in the treatment of IS. This need is even more important for infants and toddlers still sick after being treated with medicine that is already available. This is a multi-center study to evaluate the efficacy and safety of Cannabidiol Oral Solution (CBD) in the treatment of children aged 6 months through 36 months with a diagnosis of infantile spasms who have not responded to first line therapies. The overall study duration is expected to be 64 weeks for those subjects who respond to CBD treatment. The maximum possible study duration for each patient is approximately 64 weeks, however a subject will be deemed to have completed the study after 58 weeks.

Key facts

Study ID

NCT02551731

Run by

INSYS Therapeutics Inc

People needed

9

Starts

2016-01-27

Expected to finish

2016-09-06

Last updated by the study team

2018-09-19

Who can join

Age: 1 and older, up to 3. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meets protocol-specified criteria for qualification, including infantile spasms
• Parent(s)/caregiver(s) fully comprehend and sign the informed consent form, understand all study procedures, and can communicate satisfactorily with the Investigator and study coordinator.

You may not qualify if…

• History or current use of over-the-counter medications, dietary supplements, or drugs outside protocol-specified parameters
• Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
• the safety or well-being of the participant or study staff
• the analysis of results
• During the Safety Treatment and Follow-up Periods, subjects are not to receive the following:
• any cannabinoids (CBD, Δ9-tetrahydrocannabinol (THC), hemp oil, Realm Oil or marijuana)
• any other investigational drug or investigational device

Where it is running

• Mattel Children's Hospital at UCLA — Los Angeles, California, United States
• University of California - San Francisco — San Francisco, California, United States
• Miami Children's Hospital — Miami, Florida, United States
• Beaumont Health System — Royal Oak, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.